Adam Palayew
Overview
Explore the profile of Adam Palayew including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1946
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Palayew A, Banta-Green C, Lamont M, Damper D, Moreno C, Goodreau S, et al.
Int J Drug Policy
. 2024 Mar;
127():104389.
PMID: 38522176
Background: Opioid overdose mortality in the US has exceeded one million deaths over the last two decades. A regulated opioid supply may help prevent future overdose deaths by reducing exposure...
2.
Cooke G, Flower B, Cunningham E, Marshall A, Lazarus J, Palayew A, et al.
Lancet Gastroenterol Hepatol
. 2024 Feb;
9(4):346-365.
PMID: 38367629
The top 20 highest burdened countries (in disability-adjusted life years) account for more than 75% of the global burden of viral hepatitis. An effective response in these 20 countries is...
3.
Palayew A, Knudtson K, Purchase S, Clark S, Possehl L, Healy E, et al.
Harm Reduct J
. 2023 Aug;
20(1):102.
PMID: 37533085
Background: Since 2019, multiple HIV outbreaks occurred among people who inject drugs (PWID) in Minnesota. Syringe service programs (SSPs) are evidence-based programs that reduce the spread of HIV. We conducted...
4.
Mugwanya K, Palayew A, Schaafsma T, Irungu E, Bukusi E, Mugo N, et al.
J Int AIDS Soc
. 2023 Jul;
26(7):e26137.
PMID: 37403405
Introduction: Effective PrEP use is critical for impact, but data are limited on common patterns of continuation and coverage among persons using PrEP in real-world settings. Methods: Data are from...
5.
Bonn M, Palayew A, Touesnard N, Brothers T, Bodkin C
J Stud Alcohol Drugs
. 2023 Jun;
84(4):648-650.
PMID: 37306367
No abstract available.
6.
Brothers S, Palayew A, Simon C, Coulter A, Strichartz K, Voyles N, et al.
Harm Reduct J
. 2023 Mar;
20(1):31.
PMID: 36894968
Background: During COVID-19, the Substance Abuse and Mental Health Services Administration (SAMHSA) allowed Methadone Maintenance Treatment (MMT) programs to relax in-person MMT requirements to reduce COVID-19 exposure. This study examines...
7.
Laniece Delaunay C, Greenwald Z, Minoyan N, Artenie A, Jeong D, Marathe G, et al.
Can Liver J
. 2022 Aug;
4(1):4-7.
PMID: 35991473
No abstract available.
8.
Lazarus J, Mark H, Villota-Rivas M, Palayew A, Carrieri P, Colombo M, et al.
J Hepatol
. 2021 Dec;
76(4):771-780.
PMID: 34895743
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, yet largely underappreciated liver condition which is closely associated with obesity and metabolic disease. Despite affecting an estimated...
9.
Mah J, Lieu A, Palayew M, Alipour P, Kong L, Song S, et al.
CMAJ Open
. 2021 Jul;
9(3):E718-E727.
PMID: 34257090
Background: As in other jurisdictions, the demographics of people infected with SARS-CoV-2 changed in Quebec over the course of the first COVID-19 pandemic wave, and affected those living in residential...
10.
Lazarus J, Kakalou C, Palayew A, Karamanidou C, Maramis C, Natsiavas P, et al.
Liver Int
. 2021 May;
41(10):2295-2307.
PMID: 34022107
Background: People with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are stigmatized, partly since 'non-alcoholic' is in the name, but also because of obesity, which is a common...